Work

Abstract CT215: RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (PBO+ERL) in previously untreated EGFR mutation-positive metastatic NSCLC: Next generation sequencing (NGS) results

Year: 2020

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2020-ct215

Authors: Edward Garon, Martin Reck, Kazuto Nishio, John Victor Heymach, Makoto Nishio, Silvia Novello, Luis Paz-Ares, Sanjay Popat, Santiago Ponce Aix, Sameera Wijayawardana, Rebecca R. Hozak, Carla Visseren-Grul, Kazuhiko Nakagawa

Institutions: University of California, Los Angeles, German Center for Lung Research, Kindai University, The University of Texas MD Anderson Cancer Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, University of Turin, Hospital Universitario 12 De Octubre, Royal Marsden NHS Foundation Trust, Eli Lilly (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3081911955

Cites:

Cited by: 1

Related to: 10